Transcatheter Tricuspid Repair Lowers Mortality and Hospitalization Risks

<>

Evaluating the TRIC-I-HF Trial Findings

Tricuspid regurgitation is a heart valve disorder where the tricuspid valve leaks, causing the right side of the heart to enlarge. Severe cases lead to debilitating heart failure symptoms like fatigue, shortness of breath, and fluid overload, while significantly increasing mortality rates. Traditional medical options remain limited for these patients.

Led by Principal Investigators Professor Jörg Hausleiter and Professor Thomas Stocker of Ludwig-Maximilians-University in Munich, Germany, the TRIC-I-HF trial evaluated whether adding transcatheter tricuspid valve repair to medical therapy improves clinical outcomes over medical therapy alone. The study enrolled 360 patients across 29 high-volume heart valve centres in Germany. Patients had a mean age of 80.3 years, and 56.4% were women. Of those undergoing the intervention, 98% received tricuspid transcatheter edge-to-edge repair (T-TEER).

Researchers met both primary endpoints. The first endpoint—a composite of all-cause mortality, heart failure hospitalization, and failure to achieve quality-of-life improvement at one year—favored the repair group, yielding a win ratio of 2.42 (95% CI 1.76 to 3.33; p<0.001), according to data reported at the European Society of Cardiology Congress.

At the three-year mark, participants given the procedure showed a much higher rate of freedom from the co-primary endpoint consisting of all-cause mortality or heart failure hospitalization than those treated with medical management exclusively (52.4% vs. 21.0%; hazard ratio 0.40; 95% CI 0.29 to 0.55; p<0.001).

Impact on Hard Clinical Outcomes and Quality of Life

Previous studies established that transcatheter interventions reduce regurgitation and improve patient-reported quality of life. However, their specific effects on heart failure hospitalizations and mortality were previously unclear.

Professor Thomas Stocker noted that the trial enrolled patients in advanced disease stages who faced a higher risk for future heart failure events than participants in earlier randomized controlled trials. Increased risk was defined by a heart failure hospitalization in the prior year, cardiorenal syndrome, or cardiohepatic syndrome.

"Among these high-risk patients, transcatheter tricuspid valve repair on top of medical therapy resulted not only in quality-of-life improvements but also in meaningful and sustained reductions in hard clinical outcomes, which has not been demonstrated before with the intervention," Professor Jörg Hausleiter stated. He added that early separation of event curves underscores the immediate benefit of the procedure.

Frequently Asked Questions

What is severe tricuspid regurgitation?

It is a heart valve disorder where the tricuspid valve fails to close tightly, allowing blood to leak backward and causing the right side of the heart to enlarge. This leads to severe fatigue, shortness of breath, and heart failure.

What did the TRIC-I-HF trial demonstrate?

According to data published in the New England Journal of Medicine, transcatheter tricuspid valve repair combined with medical therapy significantly reduced heart failure hospitalizations and all-cause mortality while improving quality of life compared to medical therapy alone.

How was the procedure performed in the study?

Of the patients who underwent the intervention in the trial, 98% were treated using tricuspid transcatheter edge-to-edge repair (T-TEER).

What were the patient demographics in the study?

The trial evaluated 360 patients with a mean age of 80.3 years, of whom 56.4% were women, treated across 29 high-volume heart valve centres in Germany.

---